Cutaneous busulfan effect in patients receiving bone-marrow transplantation.
Epidermal keratinocytes with abnormally large nuclei were found in 12 of 13 patients who received high-dose busulfan and cyclophosphamide prior to receiving bone-marrow transplantation for treatment of hematological malignancies. These cells were similar to those previously described in the lungs, cervix and bladder of patients on long-term busulfan therapy. Marked keratinocyte nuclear abnormalities were not observed in bone-marrow transplant recipients who received a preparatory regimen of cyclophosphamide and total-body irradiation. This histologic cutaneous busulfan effect was transient and was unrelated to the development of graft-versus-host reaction.
D000328:Adult; D001706:Biopsy; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000009:adverse effects* / Q000627:therapeutic use; D002467:Cell Nucleus / Q000187:drug effects; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007945:Leukemia, Lymphoid / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000628:therapy; D008297:Male; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D014916:Whole-Body Irradiation
D003520:Cyclophosphamide; D002066:Busulfan